TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Biotech-IgG Equity AB (publ)
Closing information (x1000 EUR)
Closing information | 2022/12 | 2021/12 | 2020/12 |
Turnover | 1,104 | 541 | 1,958 |
Financial expenses | 370 | 53 | 91 |
Earnings before taxes | -7,713 | 220 | -450 |
EBITDA | 86 | -67 | -354 |
Total assets | 8,048 | 17,046 | 905 |
Current assets | 2,541 | 1,621 | 838 |
Current liabilities | 2,761 | 4,444 | 274 |
Equity capital | 4,954 | 12,602 | 517 |
- share capital | 6,847 | 6,808 | 836 |
Employees (average) | 2 | 2 | 2 |
Financial ratios
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Solvency | 61.6% | 73.9% | 57.1% |
Turnover per employee | 552 | 270 | 979 |
Profit as a percentage of turnover | -698.6% | 40.7% | -23.0% |
Return on assets (ROA) | -91.2% | 1.6% | -39.7% |
Current ratio | 92.0% | 36.5% | 305.8% |
Return on equity (ROE) | -155.7% | 1.7% | -87.0% |
Change turnover | 606 | -1,381 | -1,962 |
Change turnover % | 122% | -72% | -50% |
Chg. No. of employees | 0 | 0 | -1 |
Chg. No. of employees % | 0% | 0% | -33% |
Total value of public sale
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.